218 related articles for article (PubMed ID: 26524883)
1. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
4. Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.
Ito K; Fujizuka Y; Ishikura K; Cook B
Int J Clin Oncol; 2014 Oct; 19(5):782-92. PubMed ID: 25135462
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
6. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
[TBL] [Abstract][Full Text] [Related]
8. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
[TBL] [Abstract][Full Text] [Related]
10. [proPSA: a precursor of prostate-specific antigen, may improve the early diagnosis of prostate cancer].
Sela BA; Doolman R
Harefuah; 2011 May; 150(5):466-9, 489. PubMed ID: 21678645
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
12. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
[TBL] [Abstract][Full Text] [Related]
13. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
Hori S; Blanchet JS; McLoughlin J
BJU Int; 2013 Oct; 112(6):717-28. PubMed ID: 22759214
[TBL] [Abstract][Full Text] [Related]
14. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Zhang MZ; Lu YP
Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Chen YT; Tuan LP; Chen HW; Wei IA; Chou MY; Chen HM; Tyan YC; Chen SF
Anal Chem; 2015 Jan; 87(1):545-53. PubMed ID: 25427836
[TBL] [Abstract][Full Text] [Related]
16. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review.
Pecoraro V; Roli L; Plebani M; Trenti T
Clin Chem Lab Med; 2016 Jul; 54(7):1123-32. PubMed ID: 26609863
[TBL] [Abstract][Full Text] [Related]
18. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Mikolajczyk SD; Rittenhouse HG
Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.
Filella X; Giménez N
Clin Chem Lab Med; 2013 Apr; 51(4):729-39. PubMed ID: 23154423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
